EUVIMEDEUVIMED entdecken
Crossref

Asia Pacific Gastroesophageal Cancer Congress (APGCC) 2024 consensus statement on stage 2 and 3 locally advanced gastric and Siewert 3 junctional adenocarcinoma

Yoshio Masuda, Kang Ler Fong, Danson Yeo, Charleen Yeo, Koy Min Chue, Said Bani Araba, Chiew Woon Lim, Baldwin Yeung, June Lee, Jinlin Lin, Claramae Chia, Matthew Ng und 33 weitere

Journal of Gastroenterology · 2025

DOI: 10.1007/s00535-025-02266-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gastroenterology, 2025. Verfasst von Yoshio Masuda und 44 weiteren Autor:innen. Beteiligte Einrichtung: Department of Upper Gastrointestinal & Bariatric Surgery, Division of Surgery, Singapore General Hospital, Singapore, Singapore. Hauptthemen laut MEDLINE: Stomach Neoplasms, Adenocarcinoma, Esophageal Neoplasms, Esophagogastric Junction. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 58 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: While the development in multimodal therapies has helped improve treatment outcomes for patients with locally advanced gastric adenocarcinoma (LAGC), there still exist disparities in opinion with an optimal treatment plan. This consensus hopes to provide clinicians with structured guidelines to aid in the decision-making for treatment options for LAGC. METHODS: The consensus statement was initiated by establishing a taskforce in collaboration with the Asia Pacific Gastroesophageal Cancer Congress (APGCC) and a multidisciplinary expert panel was selected. Clinical questions on LAGC where perceived variance in practice or opinion may exist were formulated. Studies involving patients with Stage 2 or 3 gastric or Siewert 3 junctional cancers with treatment arms of perioperative chemotherapy, neoadjuvant chemotherapy, adjuvant chemotherapy, immunotherapy and surgery were included. A total of two rounds of voting were performed. Consensus was determined to be reached when a single answer or a combination of either "strongly agree/agree" or "strongly disagree/disagree" responses exceeded 75%. RESULTS: A total of thirteen clinical questions were developed. They were identified through five main categories: Distal LAGC, Proximal LAGC, Deficient mismatch repair tumors, Chemotherapy and Immunotherapy, and Elderly/Unfit patients. After two rounds of voting by our multidisciplinary expert panel, eleven out of a total thirteen clinical questions had reached consensus. No consensus was reached for two clinical questions. CONCLUSION: The APGCC consensus statement aims to guide clinicians in the treatment options for LAGC and Siewert 3 junctional cancer and has clarified some of the roles of perioperative chemotherapy and immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsAdenocarcinomaEsophageal NeoplasmsEsophagogastric JunctionHumansNeoplasm StagingChemotherapy, AdjuvantNeoadjuvant TherapyAsiaCombined Modality TherapyImmunotherapy

Stichwörter der Autor:innen

ChemotherapyGastrectomyGastric cancer surgeryImmunotherapyLocally advanced gastric adenocarcinomaModified Delphi consensus

Autor:innen und Institutionen

  • Department of Upper Gastrointestinal & Bariatric Surgery, Division of Surgery, Singapore General Hospital, Singapore, Singapore.
  • Ministry of Health Holdings, Singapore, Singapore.
  • Upper Gastrointestinal & Bariatric Surgery Service, Department of General Surgery, Tan Tock Seng Hospital, Singapore, Singapore.
  • Upper Gastrointestinal & Bariatric Surgery Service, Department of General Surgery, Sengkang General Hospital, Singapore, Singapore.
  • Division of General Surgery (Upper Gastrointestinal Surgery), Department of Surgery, National University Hospital, Singapore, Singapore.
  • Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.

ORCID-Profile: Jimmy So

Zitieren

APA

Masuda, Y., Fong, K. L., Yeo, D., Yeo, C., Chue, K. M., Araba, S. B., Lim, C. W., Yeung, B., Lee, J., Lin, J., Chia, C., Ng, M., Ng, K., Samol, J., Chia, D., Teh, J. L., Sundar, R., Yong, W. P., Tan, H. L., …, & Tan, J. (2025). Asia Pacific Gastroesophageal Cancer Congress (APGCC) 2024 consensus statement on stage 2 and 3 locally advanced gastric and Siewert 3 junctional adenocarcinoma. Journal of Gastroenterology. https://doi.org/10.1007/s00535-025-02266-4

Vancouver

Masuda Y, Fong KL, Yeo D, Yeo C, Chue KM, Araba SB, et al. Asia Pacific Gastroesophageal Cancer Congress (APGCC) 2024 consensus statement on stage 2 and 3 locally advanced gastric and Siewert 3 junctional adenocarcinoma. Journal of Gastroenterology. 2025. doi:10.1007/s00535-025-02266-4

BibTeX
@article{Masuda2025,
  author = {Masuda, Yoshio and Fong, Kang Ler and Yeo, Danson and Yeo, Charleen and Chue, Koy Min and Araba, Said Bani and Lim, Chiew Woon and Yeung, Baldwin and Lee, June and Lin, Jinlin and Chia, Claramae and Ng, Matthew and Ng, Kennedy and Samol, Jens and Chia, Daryl and Teh, Jun Liang and Sundar, Raghav and Yong, Wei-Peng and Tan, Hon Lyn and Muro, Kei and Lordick, Florian and Wainburg, Zev and Tan, Bo Chuan and Kim, Guowei and Suda, Koichi and Law, Simon and Sano, Takeshi and Gurunathan, Ramesh and Chiu, Philip and Woo, Emile and Duong, Cuong and Yang, Han-Kwang and Long, Vo Duy and Kim, Hyung Ho and Mahendren, Han Alexander and Lee, Hyuk Joon and Samarasam, Inian and Gotoda, Takuji and Liew, Reis and Shabbir, Asim and Aung, Myint Oo and Terashima, Masanori and Cheong, Edward and So, Jimmy and Tan, Jeremy},
  title = {Asia Pacific Gastroesophageal Cancer Congress (APGCC) 2024 consensus statement on stage 2 and 3 locally advanced gastric and Siewert 3 junctional adenocarcinoma},
  journal = {Journal of Gastroenterology},
  year = {2025},
  doi = {10.1007/s00535-025-02266-4}
}
Kostenlos starten →